Roche announced positive
results from a Phase I trial of R1507, a human monoclonal antibody to
target IGF-1R (insulin-like growth factor receptor), in patients with solid
tumors. IGF-1 is one of the most potent natural activators of the AKT and
MAPK signaling pathways, which promote cell growth and cell survival. The
IGF-1R pathway has also been shown to have an important role in mediating
the resistance to cytotoxic drugs and EGFR/HER2-targeted agents. The
results were reported during the AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics, held in San Francisco.
Study Results
In the Phase I study, R1507 was administered by intravenous infusion.
Nine of 34 adult patients with advanced solid tumors experienced disease
stabilization. Four of the seven heavily pretreated patients with Ewing's
sarcoma demonstrated clinical benefit with two of these patients achieving
durable, objective partial responses.
Once a week administration of R1507 was well tolerated with very few
side effects. Treatment with R1507 was not associated with the typical
side-effects normally observed with cancer therapy (e.g., low blood counts,
infection, hair loss, severe nausea and vomiting). The most frequent side
effects observed were fatigue, anorexia and weight loss, symptoms that are
commonly observed in patients with advanced cancer.
"We are very encouraged by these early results with R1507 in patients
with refractory Ewing's sarcoma," said Kapil Dhingra, MD, Head, Oncology
Disease Biology Area at Roche. "As a result, we have given this program a
very high priority as we believe this molecule has the potential to be very
beneficial in treating patients with sarcoma as well as a variety of other
solid tumors."
The antibody (R1507) was initially developed under Roche's broad
antibody development collaboration with Genmab, which began in 2001.
The Phase I study is being conducted at four sites in the U.S.,
including the University of Colorado Cancer Center (Aurora, CO), The
University of Texas M.D. Anderson Cancer Center (Houston, TX), Cancer
Institute of New Jersey (New Brunswick, NJ) and The Institute for Drug
Development (San Antonio, TX). R1507 has also been investigated in 26
patients on a three week schedule in the Phase I study. This treatment
schedule was also generally well tolerated with a side effect profile
similar to the weekly schedule.
"This drug attacks the IGF pathway and may provide a new class of drugs
to treat a variety of cancers, including breast, prostate, colon, melanoma,
myeloma and a variety of sarcomas, which could greatly add to the way that
we currently treat these patients," says Stephen Leong, M.D., assistant
professor of Medical Oncology at the University of Colorado Cancer Center
and lead author of the abstract.
Razelle Kurzrock, MD, investigator at the M.D. Anderson Cancer Center
and the senior author of the abstract, noted that some of the responses
were very impressive. For instance, one 28 year-old Ewing's sarcoma patient
with large tumors unresponsive to many other treatments showed dramatic
tumor shrinkage within six weeks, without side effects. "This is one of the
best responses I've seen in over 20 years of oncology experience," stated
Dr. Kurzrock.
Based on these initial results with R1507, Roche plans to conduct
additional trials and work with a global consortium of sarcoma experts,
including the Sarcoma Alliance for Research through Collaboration (SARC).
"We are very excited about our collaboration with SARC, which represents a
new approach to sarcoma clinical trials, and we look forward to combining
our expertise with that our colleagues at SARC to expedite new sarcoma
treatments," added Dhingra.
"We are excited to be partnering with Roche on the development of a new
treatment against an important target, which could result in a potential
breakthrough treatment for sarcoma as well as other cancers," said Laurence
Baker, DO, professor of Medicine and Pharmacology at the University of
Michigan and the Executive Director, SARC. "With Roche's considerable
expertise in oncology and SARC's vast network of physicians and
institutions, we look forward to determining the potential of R1507 in this
important disease area."
About Ewing's Sarcoma
The Ewing's family of tumors (EFT) includes primary tumors of bone
(classic Ewing's sarcoma, primitive neuroectodermal tumor, and Askin tumor)
and extraosseous primary tumors {National Cancer Institute}. Studies using
immunohistochemical markers, cytogenetics, molecular genetics, and tissue
culture indicate that these tumors are all derived from the same primordial
stem cell. EFTs account for 4 percent of childhood and adolescent
malignancies. The estimated incidence (US) is approximately 300 new cases
per year. The median age for patients with EFT is 15 years and more than 50
percent of patients are adolescents. There is a slight male predominance
and the lower limbs are affected in 40 percent of the patients.
Approximately 20 to 30 percent of the patients with ETB have overt
metastases at the time of diagnosis. However, outcomes for patients with
metastatic disease have improved little during the last 20 years.
Approximately 25-30 percent survival could be achieved with current
therapies for patients who present with metastatic disease at initial
diagnosis.
About Roche
Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S.
pharmaceuticals headquarters of the Roche Group, one of the world's leading
research-oriented healthcare groups with core businesses in pharmaceuticals
and diagnostics. For more than 100 years in the U.S., Roche has been
committed to developing innovative products and services that address
prevention, diagnosis and treatment of diseases, thus enhancing people's
health and quality of life. An employer of choice, in 2007 Roche was named
Top Company of the Year by Med Ad News and one of the Top 20 Employers
(Science magazine). In 2006, Roche was ranked the No. 1 Company to Sell For
(Selling Power), and one of AARP's Top Companies for Older Workers, and in
2005, Roche was named one of Fortune magazine's Best Companies to Work For
in America. For additional information about the U.S. pharmaceuticals
business, visit our websites: rocheusa or roche.us.
About SARC
The purpose of the Sarcoma Alliance for Research through Collaboration
(SARC) is to engage all appropriate and necessary resources to cure and
prevent sarcoma. SARC brings together expert sarcoma researchers and
clinicians from 29 centers of excellence in the United States. SARC by the
charter, promotes international collaboration in sarcoma clinical trials
through is association with European sarcoma experts. SARC is unique as a
clinical trial organization in that its trials at the inception include
pediatric and medical patients with sarcoma, because sarcomas affect people
of all ages. SARC is a 501c3, non-profit organization that is headquartered
in Ann Arbor, Michigan.
Hoffmann-La Roche Inc.
roche.us
Комментариев нет:
Отправить комментарий